DGM
Darwin Global Management Portfolio holdings
AUM
$2.38B
This Quarter Return
+53.03%
1 Year Return
+81.43%
3 Year Return
+6,053.69%
5 Year Return
–
10 Year Return
–
AUM
$751M
AUM Growth
+$751M
(+47%)
Cap. Flow
+$210M
Cap. Flow
% of AUM
28%
Top 10 Holdings %
Top 10 Hldgs %
97.18%
Holding
17
New
9
Increased
3
Reduced
–
Closed
5
Top Buys
| 1 |
Vaxcyte
PCVX
|
$148M |
| 2 |
Nuvalent
NUVL
|
$104M |
| 3 |
Biohaven
BHVN
|
$80.8M |
| 4 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$78.6M |
| 5 |
Beam Therapeutics
BEAM
|
$70M |
Top Sells
| 1 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$238M |
| 2 |
TG Therapeutics
TGTX
|
$69.1M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
$62.8M |
| 4 |
Cytokinetics
CYTK
|
$50.1M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
$7.03M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vaxcyte
PCVX
$4B
| $188M | 25.02% | 2,750,804 +2,170,845 | +374% | +$148M |
|
|
2
Nuvalent
NUVL
$5.52B
| $108M | 14.36% | 1,436,964 +1,379,266 | +2,390% | +$104M |
|
3
Keros Therapeutics
KROS
$618M
| $95.1M | 12.66% | 1,435,950 +375,523 | +35% | +$24.9M |
|
|
4
Biohaven
BHVN
$1.63B
| $80.8M | 10.75% | +1,476,974 | New | +$80.8M |
|
|
ALPN
5
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $78.6M | 10.46% | +1,982,016 | New | +$78.6M |
|
|
6
Beam Therapeutics
BEAM
$1.66B
| $70M | 9.32% | +2,119,598 | New | +$70M |
|
7
Apogee Therapeutics
APGE
$2.17B
| $55.3M | 7.36% | +832,198 | New | +$55.3M |
|
8
Xencor
XNCR
$580M
| $24.6M | 3.27% | +1,109,650 | New | +$24.6M |
|
9
Spyre Therapeutics
SYRE
$996M
| $17.9M | 2.39% | +473,200 | New | +$17.9M |
|
|
ELEV
10
DELISTED
Elevation Oncology
ELEV
| $12M | 1.59% | +2,332,928 | New | +$12M |
|
11
Tourmaline Bio
TRML
$601M
| $10.6M | 1.42% | +465,000 | New | +$10.6M |
|
12
Merck
MRK
$210B
| $10.5M | 1.4% | +79,600 | New | +$10.5M |
|
|
13
Cytokinetics
CYTK
$4.23B
| – | – | -600,000 | Closed | -$50.1M |
|
|
14
MoonLake Immunotherapeutics
MLTX
$3.54B
| – | – | -1,039,289 | Closed | -$62.8M |
|
|
SWTX
15
DELISTED
SpringWorks Therapeutics
SWTX
| – | – | -192,734 | Closed | -$7.03M |
|
|
16
TG Therapeutics
TGTX
$4.65B
| – | – | -4,046,598 | Closed | -$69.1M |
|
|
AMAM
17
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| – | – | -16,688,636 | Closed | -$238M |
|